Harmony Biosciences Holdings, Inc. cotiza a 37.03 USD y tiene una capitalización bursátil de $2.2B. En los últimos 12 meses ha facturado $960M con un margen de flujo de caja libre del 40.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $1.50 | $0.79 | $0.57 |
| Estimado | $1.47 | $1.15 | $0.93 | $1.07 |
| Sorpresa | — | +30.4% | -15.1% | -46.7% |
| Métrica | HRMY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 77.2% | 57.0% | +20.1% |
| Operating Margin | 24.0% | -38.6% | +62.6% |
| Net Margin | 18.3% | -33.6% | +51.8% |
| FCF Margin | 40.1% | -13.9% | +53.9% |
| ROE | 18.2% | -40.4% | +58.6% |
| ROA | 12.5% | -32.0% | +44.5% |
| Current Ratio | 3.60 | 2.84 | +0.76 |
| Debt / Equity | 0.19 | 0.28 | -0.09 |